Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.04.2024 | Case report

Obinutuzumab

Lack of efficacy

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Pinto A, et al. Obinutuzumab-Based Immunochemotherapy Mitigates Early Progression Risk with a Substantial 2-Year Progression-Free Survival (PFS) in Patients with Previously Untreated Advanced Follicular Lymphoma and a FLIPI Score >=2: An Interim Analysis of the Ambispective Urban Study. Blood 140 (Suppl.): 3638-3641, Nov 2022. Available from: URL: https://dx.doi.org/10.1182/blood-2022-165977 [abstract] Pinto A, et al. Obinutuzumab-Based Immunochemotherapy Mitigates Early Progression Risk with a Substantial 2-Year Progression-Free Survival (PFS) in Patients with Previously Untreated Advanced Follicular Lymphoma and a FLIPI Score >=2: An Interim Analysis of the Ambispective Urban Study. Blood 140 (Suppl.): 3638-3641, Nov 2022. Available from: URL: https://​dx.​doi.​org/​10.​1182/​blood-2022-165977 [abstract]
Metadaten
Titel
Obinutuzumab
Lack of efficacy
Publikationsdatum
01.04.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-56490-4

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Denosumab

Case report

Diltiazem

Case report

Metoprolol

Case report

Metformin